Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING LLC
RANDOX LABORATORIES

Biomarker Identified for Head and Neck Cancers

By Labmedica International staff writers
Posted on 28 Aug 2014
Sequenom\'s MassARRAY Analyzer 4 mass spectrometry system
The MassARRAY Analyzer 4 mass spectrometry system (Photo courtesy of SEQUENOM)
Evidence has been found suggesting that the deleterious health effects of a mutated gene may in large part be due to other genetic abnormalities, at least in head and neck squamous cell carcinoma (HNSCC).

The high mortality rates among head and neck cancer patients tend to occur only when mutations in the tumor suppressor gene coincide with missing segments of genetic material on the cancer genome's third chromosome.

Scientists at the University of California, San Diego (La Jolla, CA, USA) and their colleagues analyzed the complete genomic signatures of 250 cases of squamous cell head and neck cancer extracted from The Cancer Genome Atlas, a repository of sequenced cancer genomes for more than 20 different types of human cancers maintained by the US National Cancer Institute (Bethesda, MD, USA). All of the tumors were from patients younger than 85 years of age.

Of these, 179 had both mutations; 50 had one of the two mutations; and 22 had neither mutation. Comparisons with patient outcome data showed that half of patients with both mutations would likely die of cancer within two years, while 66 percent of patients with one or neither mutation would be expected to live five years or more. These survival statistics were independent of the patients' clinical cancer stage. To patients with these cancers, the results mean that there may be therapeutic value in testing tumors for the two genetic identifiers, known as a tumor protein 53 (TP53) mutation and a 3p deletion (short for deletions of genetic information on the short arm "p" of the third chromosome).

The human papilloma virus (HPV) is implicated in the growing epidemic of head and neck cancers in otherwise healthy adults. It is believed that the virus can coopt the activity of TP53, affecting cells in much the same way as a TP53 mutation but without causing a mutation. For this reason, the analysis examined HPV-positive and HPV-negative tumors separately. HPV status was deduced from a polymerase chain reaction (PCR)-based MassARRAY Assay (Sequenom; San Diego, CA, USA) diagnostic provided on the data portal for cases where sequence-based data were not available. The team discovered that among human papilloma virus (HPV)-positive tumors, the most aggressive cancer cases were also highly linked to the presence of 3p deletions.

Quyen Nguyen, MD, PhD, associate professor of Otolaryngology-Head and Neck Surgery and a senior author of the study said, “We are in the early stages of being able to personalize head and neck cancer treatments based on the tumor's actual biology, the same as what is done with breast cancers. In the past, treatments have been based largely on the size and location of the tumor. Now, we know that some large tumors may respond to less aggressive treatment while some small tumors may need intensified treatment. This will have a huge impact for patients.” The study was published on August 3, 2014, in the journal Nature Genetics.

Related Links:

University of California, San Diego 
US National Cancer Institute
Sequenom




Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
Free digital version edition of LabMedica International sent by email on regular basis
Free print version of LabMedica International magazine
(available only outside USA and Canada).
Free and unlimited access to back issues of LabMedica International in digital format
Free LabMedica International Newsletter sent every 2 weeks containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!


Click here to Register

Sign in: Registered website members
Username: Password:
Forgot username/password? Click here!
Sign in: Registered magazine subscribers
Subcode: Last Name:
What is SUBCODE?


MEDLAB Asia
CELLAVISION AB
KARL HECHT GMBH & CO KG

Channels

Genetic Tests

view channel
Image: For each chromosome, key SNPs are displayed above the chromosome and non-key SNPs below the chromosome, enabling users to determine the accuracy of haploblock calling. SNPs failed to be called are displayed as white points in the middle of the chromosome (Photo courtesy of Illumina).

Karyomapping Proposed as Alternative to Preimplantation Genetic Diagnosis for Evaluation of IVF Embryos

British researchers have suggested that karyomapping is a viable and cost-effective method for detecting a wide range of genetic diseases in IVF (in vitro fertilization) embryos. Preimplantation Genetic... Read more

Industry News

view channel
Image: Positive case of lung tissue stained for ALK with VENTANA ALK (D5F3) CDx Assay, a companion diagnostic immunohistochemical test in the final stages of the FDA premarket approval process (Photo courtesy of Ventana Medical Systems and PRNewsFoto).

Premarket Approval Sought for CDx Test to Benefit Lung Cancer Patients

Ventana Medical Systems, Inc. (Tucson, AZ, USA) has announced its US Food & Drug Administration (FDA) final stage submission for premarket approval (PMA) of its companion diagnostic (CDx) immunohistochemistry... Read more
 

Events

05 Mar 2015 - 08 Mar 2015
18 Mar 2015 - 20 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.